Search Results
90 results
Your search is now limited to «Genentech» expert search.
Company Drug/Device Medical Condition Status Sutro Biopharma, Inc. STRO-002 ovarian and endometrial cancers Phase I trial initiated enrolling 160 female subjects with advanced relapsed and/or progressive ovarian, fallopian, primary peritoneal or endometrial cancer Cytovation AS CyPep-1 HPV-induced warts Phase I trial initiated enrolling 58 subjects with cutaneous warts at the Centre for Human Drug Research [...]
More from CenterWatch Clinical Trials Today Headlines:
FierceMedicalDevices 03/21/2019 14:08
At Genentech, Lieu served as VP of early clinical development for the Roche subsidiary's noncancer work, including in ophthalmology, metabolism, neurology and inflammation.
More from FierceMedicalDevices:
Xconomy 03/20/2019 16:04
Lieu is joining South San Francisco, CA-based NGM from Roche’s Genentech unit, where he was vice president of early clinical development.
More from Xconomy:
GlobeNewswire 03/19/2019 05:00
The progress of our collaboration with Genentech further demonstrates Affimed’s expertise in innate immunity and the potential of our fit-for-purpose ROCK® platform to generate efficacious oncology therapies,” said Dr. Adi Hoess, Chief Executive Officer of Affimed. 03/19/2019 00:10
Monday, Mar 18, 2019 Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer (ES-SCLC) First new initial treatment option approved by the U.S. Food and Drug Administration (FDA) for people with ES-SCLC in more than 20 years South San Francisco, CA -- March 18, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with...
More from 03/18/2019 21:30
Roche Holding AG:
More from
Business Wire 03/18/2019 21:15
For those who qualify, Genentech offers patient assistance programs for people taking Tecentriq through Genentech Access Solutions.
More from Business Wire:
PR Newswire 03/12/2019 07:25
EXTON, Pa., March 12, 2019 /PRNewswire/ -- Expanding adoption of Genentech's Ocrevus among US neurologists has significantly and persistently increased the rate of disease-modifying therapy (DMT) treatment among patients with primary progressive multiple sclerosis (PPMS) compared to two...
More from PR Newswire:
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of.
More from Global Banking & Finance Review:
Genentech, however, charges and is paid for all the medication regardless of the amount that must be discarded.
More from Middle East North Africa Financial Network (MENAFN):
Pharmafile 02/06/2019 07:03
As also noted in the terms, Genentech will handle commercialisation of such products worldwide, with Xencor able to co-promote them in the US if it chooses to.
More from Pharmafile:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications